Study to Reduce Symptoms of Premature Beats With Ranolazine

Inclusion Criteria: * Subjects male and female 18 years and older * Symptoms of palpitations * Greater than or equal to 1,000 Ventricular Premature Beats during 24-hour electrocardiographic monitoring * Completion of a consent form prior to pre-randomization Holter monitor Exclusion Criteria: * Moderate to severe symptomatic heart failure, New York Heart Association Class III/IV * Moderate to severe symptomatic angina, Canadian Cardiovascular Classification III/IV * Moderate to severe structural heart disease in the absence of an implantable cardiac defibrillator in a subject who would otherwise be eligible for a defibrillator (e.g. history of myocardial infarction and a left ventricular ejection fraction less than 30%) * Clinically significant hepatic disease (cirrhosis or chronic hepatitis) or abnormal liver associated enzymes greater than three times the upper limits of normal * A baseline corrected QT interval greater than or equal to 500msec or history of congenital channelopathy (long QT syndrome, Brugada syndrome) or torsades de pointes. * Treatment with agents known to prolong the QTc interval * Treatment with agents that are potent or moderately potent inhibitors of CYP3A, to include, but is not limited to the following: ketoconazole, HIV protease inhibitors (i.e. ritonavir), macrolide antibiotics (i.e. clarithromycin), diltiazem and verapamil * Females who are pregnant, planning to get pregnant, or breast feeding ( females under the age of 55 years who have not previously undergone surgical sterilization procedures will have serum qualitative pregnancy testing) * Thyroid stimulating hormone less than 0.27 IU/mL * Serum magnesium less than 1.5mg/dL * Serum potassium less than 3.5 mEq/dL or greater than 5.0 mEq/dL * Estimated GFR less than 30 mL/min